Inventia wins Australia’s Good Design Award of the Year for Rastrum 3D bioprinter

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Each year, Good Design Australia presents prizes to the most innovative designs in various disciplines. This year, the 61st  annual Australian Good Design Awards presented the highest award—the Good Design Award of the Year—to medtech company Inventia for its Rastrum 3D bioprinter, which is designed for advancing cancer treatments.

The prestigious award has given a major boost to Australian company Inventia Life Science Pty Ltd, which was founded in 2013 with the goal of transforming the medical field—with a focus on cancer treatment—through 3D bioprinting technologies.

Some of the other awards presented were to RangerBot, an underwater robot designed to help save the Great Barrier Reef (it won the Good Design Award for Sustainability) and to Sharon Gauci, the Executive Director of Industrial Design at General Motors, who received the inaugural Women in Design Award.

Inventia Rastrum bioprinter

“The Good Design Award winners this year are an inspiring representation of the future,” said Dr Brandon Gien, CEO of Good Design Australia. “At the heart of all the winning projects is a problem (big or small) that was solved through clever, considered and meaningful design that will have a positive impact on our lives and our planet.”

Rastrum 3D bioprinter

Inventia’s novel bioprinting technology was designed for the purpose of building 3D cell structures to test different cancer therapies. More specifically, it leverages advanced microfluidics to create a realistic, three-dimensional cellular structures for testing immunotherapies.

“Rastrum makes complex 3D cell biology simple by unleashing the power of digital 3D bioprinting,” Inventia writes on its website. “With its unique technology, Rastrum places individual cell types and matrix components drop-by-drop (akin to an inkjet printer depositing pixels of colour), layer-by-layer to build a 3D cell model, giving you capability like never before to recreate in vivo biology.”

The bioprinter, whose design is remarkably compact and sleek, is capable of delivering 3D cell models at rapid rates, enabling medical professionals and researchers to screen thousands of drugs for cancer treatment. The ability to rapidly determine the efficacy of a cancer drug—in general or for a specific patient—can lead to huge improvements in patient-care and cancer research more broadly. In other words, the technology could help to eliminate much of the trial and error that goes into treating patients for cancer.

Down the line, Inventia’s Rastrum bioprinting technology could also be used for other applications, such as printing tissues and even organs.

Research 2022
Polymer AM Market Opportunities and Trends

741 unique polymer AM companies individually surveyed and studied. Core polymer AM market generated $4.6 billion...

Tess Boissonneault

Tess Boissonneault is a Montreal-based content writer and editor with five years of experience covering the additive manufacturing world. She has a particular interest in amplifying the voices of women working within the industry and is an avid follower of the ever-evolving AM sector. Tess holds a master's degree in Media Studies from the University of Amsterdam.

Related Articles

Back to top button

We use cookies to give you the best online experience and for ads personalisation. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services



Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*